Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update

Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into ...

Cardiff Oncology, Inc.: Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update

Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated mCR ...
The Motley Fool

Vistance (VISN) Q2 2026 Earnings Call Transcript

Lorentzen stated, "the memory pricing and availability environment has deteriorated faster and further than we expected," noting that this drove the reduction in full-year guidance. Treadway stated, ...

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced publication of the KINECT-PRO™ Phase 4 open-label study results demonstrating that treatment with once-daily INGREZZA® (valbenazine) ...

Nuveen Minnesota Quality Municipal Income Fund

Nuveen Minnesota Quality Municipal Income Fund is a closed ended investment trust, which engages in the provision of portfolio diversification and attractive after total tax return. The company was ...